Abstract A079: FHD286 is a BRG1/BRM ATPase inhibitor showing efficacy in NSCLC models and is applicable to NSCLC patients both as a single agent treatment and in combination with c... von Mikse, Oliver, Adam, Ammar, Elliott, GiNell, Lahr, Dave, Amaral, Victoria, Viswanathan, Priyadharshini, Johannessen, Liv, Ahmad, Hafiz, Wan, Jessica, Bellon, Steven, Hentemann, Murphy

Volltext

Abstract A056: Treatment with dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 ablates tumor-associated androgen response elements (AREs) in prostate cancer von Sandoval, Gabriel J, Centore, Richard C, Topal, Sal, Lahr, Dave, Elliott, GiNell, Gandevia, Heena, Adam, Ammar, Piel, Jessica, Nguyen, Holly M, Corey, Eva, Chen, Yu, Bellon, Steven, Hentemann, Murphy

Volltext

Abstract A060: Discovery of potent and selective EP300 degraders with anti-cancer activity von Zimmerman, Mark, Sappal, Darshan, Adam, Ammar, Adams, Benjamin, Adhikari, Ketaki, Austin, Wesley, Bullock, Breanna, DiBernardo, Julie, Dixon, Thomas, Elliot, GiNell, Ethell, Brian, Gervais, Anais, Hossain, Md Imran, Huang, David, Lahr, Dave, Lin, Mei Yun, Mayhew, David, Mizeracka, Karolina, Negretti, Solymar, Nguyen, Tyler, Prifti, Olga, Schiller, Shawn, Sherbanee, Brenna, Terry, David, Ucisik, Nihan, Wittenborn, Elizabeth, LaBonte, Laura, Daniels, Danette

Volltext

A retrospective analysis to explore the applicability of fish biomarkers and sediment bioassays along contaminated salinity transects von Schipper, Cor A., Lahr, Joost, van den Brink, Paul J., George, Steve G., Hansen, Peter-Diedrich, da Silva de Assis, Helena C., van der Oost, Ron, Thain, John E., Livingstone, Dave, Mitchelmore, Carys, van Schooten, Frederik-Jan, Ariese, Freek, Murk, Albertinka J., Grinwis, Guy C. M., Klamer, Hans, Kater, Belinda J., Postma, Jaap F., van der Werf, Bert, Vethaak, A. Dick

Volltext